Literature DB >> 2649340

The influence of different insulin regimens on quality of life and metabolic control in insulin-dependent diabetics.

G Tallroth1, B Karlson, A Nilsson, C D Agardh.   

Abstract

Administration of insulin with premeal boluses of short-acting insulin using a new injection device (Novopen) was compared with a conventional three times daily injection regimen regarding aspects of quality of life and metabolic control in insulin-dependent diabetes mellitus (IDDM). Eighteen C-peptide-negative patients with IDDM (16 men, two women, aged 31.0 +/- 7.4 years, duration of diabetes 13.0 +/- 4.6 years; mean +/- SD) participated in the study. All patients had been treated with three daily insulin injections for at least 1 year prior to the study. The patients were randomized into two groups. Group A started a 3-month treatment period with premeal injections of short-acting insulin and intermediate-acting insulin at bedtime. This period was followed by another 3 months using the initial three times daily injection regimen. Group B completed the study in the reverse order. Quality of life was assessed by using questionnaires and personal interviews by the same clinical psychologist. Metabolic control was assessed by measuring the levels of glycosylated hemoglobin. The results show that both treatment groups experienced a general improvement in mood and well-being during the period with multiple insulin injection treatment. Furthermore, during the periods of insulin pen treatment, an increased experience of freedom and less dependence on fixed meal times were noted. Overall metabolic control, insulin dosage, body weight, and number of hypoglycemic episodes did not change during the study. It is concluded that metabolic control, safety, and number of hypoglycemic episodes using premeal doses of short-acting insulin using Novopen were not different from those seen during conventional treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649340     DOI: 10.1016/0168-8227(89)90055-7

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  7 in total

1.  Quality-of-life evaluation in diabetes.

Authors:  C Eiser; J E Tooke
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

2.  The role of anxiety and depression in quality of life and symptom reporting in people with diabetes mellitus.

Authors:  D Kohen; A P Burgess; J Catalán; A Lant
Journal:  Qual Life Res       Date:  1998-04       Impact factor: 4.147

3.  Needle with a novel attachment versus conventional screw-thread needles: a preference and usability test among adults with diabetes and impaired manual dexterity.

Authors:  Birtha Hansen; Søren K Lilleøre; Gitte Ter-Borch
Journal:  Diabetes Technol Ther       Date:  2011-03-15       Impact factor: 6.118

Review 4.  What can we learn from patient-reported outcomes of insulin pen devices?

Authors:  Barbara J Anderson; Maria J Redondo
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

Review 5.  A review of 20 years' experience with the NovoPen family of insulin injection devices.

Authors:  Jørn Rex; Klaus H Jensen; Simon A Lawton
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 6.  A review of 25 years' experience with the NovoPen family of insulin pens in the management of diabetes mellitus.

Authors:  Jacob Hyllested-Winge; Klaus H Jensen; Jørn Rex
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 3.580

7.  A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus.

Authors:  Parastoo Rostami; Aria Setoodeh; Ali Rabbani; Maryam Nakhaei-Moghadam; Farnaz Najmi-Varzaneh; Nima Rezaei
Journal:  Iran J Pediatr       Date:  2014-04       Impact factor: 0.364

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.